Acepromazine (PromAce)

Acepromazine, commonly known by the brand name PromAce, is a phenothiazine tranquilizer that has been a cornerstone of equine sedation for decades. This medication provides reliable calming effects through central nervous system depression, making it valuable for a wide range of applications from pre-anesthetic preparation to transportation and handling of excitable horses. While newer sedative options have emerged, acepromazine remains one of the most commonly used tranquilizers in equine practice due to its effectiveness, familiarity, and relatively low cost.

The mechanism of action of acepromazine involves antagonism of dopamine receptors in the central nervous system, producing sedation, reduced anxiety, and decreased motor activity. Unlike alpha-2 agonist sedatives that provide both sedation and analgesia, acepromazine is primarily a tranquilizer without significant pain-relieving properties. The drug also produces peripheral effects including alpha-adrenergic blockade that results in vasodilation and can cause hypotension, particularly following intravenous administration. Understanding these mechanisms helps explain both the therapeutic effects and potential adverse reactions associated with acepromazine use.

Acepromazine is available in multiple formulations suitable for different clinical situations. Injectable solutions in concentrations of ten milligrams per milliliter are most commonly used in veterinary practice, allowing precise dosing by either intravenous or intramuscular routes. Oral formulations including tablets and granules provide convenient options for transportation or management of chronic anxiety when injectable administration is impractical. The flexibility of administration routes makes acepromazine adaptable to various clinical scenarios and owner capabilities.

The safety profile of acepromazine in horses is generally favorable when used appropriately, though several important considerations affect patient selection. The drug does not provide reliable sedation in excited or frightened horses, as adrenaline can override its effects. Hypotension from alpha-adrenergic blockade requires caution in compromised patients, and the well-documented risk of penile prolapse in stallions and geldings necessitates careful use in male horses. Veterinary guidance is essential for determining appropriate candidacy for acepromazine sedation and for establishing safe doses based on individual patient factors.

The primary indication for acepromazine in equine medicine is sedation and tranquilization for various procedures and management situations where a calmer, more cooperative patient is required. The drug produces reliable anxiety reduction and sedation in horses that are not already highly excited, making it valuable for procedures ranging from veterinary examinations to grooming of difficult horses. Acepromazine is not an analgesic and does not provide pain relief, so it is typically combined with other medications when painful procedures are anticipated.

Pre-anesthetic use represents one of the most common applications of acepromazine in equine practice. When administered prior to induction of general anesthesia, acepromazine reduces anxiety, smooths induction, and may decrease the dose of induction agents required. The sedative effect helps calm nervous horses before surgery, making the entire anesthetic process safer for both the patient and the veterinary team. Acepromazine is frequently combined with alpha-2 agonists as part of balanced sedation protocols that provide both tranquilization and analgesia.

Transportation is another major indication for acepromazine use in horses. Many horses experience significant stress during trailer loading and travel, and acepromazine can reduce anxiety and prevent dangerous behavior that puts both the horse and handlers at risk. The oral formulation is particularly convenient for transportation, as it can be administered in feed prior to loading without requiring injection. However, the drug's long duration of action means that horses may remain sedated for several hours after arrival, and its effects on thermoregulation require consideration during extreme weather conditions.

Minor procedures that require patient cooperation but are not significantly painful may be performed with acepromazine sedation alone or in combination with physical restraint. Clipping, mane pulling, ear handling, and other grooming procedures are often facilitated by acepromazine in horses that otherwise resist these activities. Veterinary examinations including auscultation, ophthalmic examination, and routine physical assessment may be performed more safely with tranquilization in uncooperative patients.

Behavioral management applications include use in horses with significant anxiety disorders, during initial training of young horses, or for management of horses that become dangerous when excited. While not a first-line behavioral medication, acepromazine can be valuable as part of a comprehensive behavior modification program. The drug may also facilitate safe handling during farrier work in horses that are difficult to shoe, though care must be taken regarding the balance and stability of sedated horses.

Dosing of acepromazine in horses follows established guidelines while allowing for individual adjustment based on patient temperament, intended use, and prior response history. The veterinarian determines appropriate doses considering factors including the horse's baseline behavior, the degree of sedation required, concurrent medications, and any conditions that might affect drug response or increase risk. Weight-based dosing provides the foundation, but experienced clinicians recognize that acepromazine response varies significantly among individual horses and that dose adjustments are often necessary.

For injectable administration, acepromazine is typically dosed in the range of 0.02 to 0.1 milligrams per kilogram, with most routine sedation using doses at the lower end of this range. Higher doses increase the depth and duration of sedation but also increase the risk of adverse effects including hypotension and prolonged recovery. Intravenous administration produces more rapid onset, typically within five to fifteen minutes, compared to intramuscular injection which may require twenty to thirty minutes for full effect. The total dose should generally not exceed 30 milligrams regardless of horse size to minimize adverse effects.

Oral acepromazine requires higher doses than injectable administration due to significant first-pass hepatic metabolism that reduces bioavailability. Typical oral doses range from 0.1 to 0.2 milligrams per kilogram, administered one to two hours before the desired effect. Oral administration is particularly useful for transportation, as the medication can be given in feed prior to loading. The longer onset time requires appropriate planning, and owners should be educated about the expected timeline for effect.

The duration of acepromazine effects is relatively long compared to alpha-2 agonist sedatives, typically lasting two to four hours depending on dose and individual metabolism, with some residual effects potentially persisting for twelve to twenty-four hours. This prolonged duration is advantageous for transportation or extended procedures but requires consideration when planning the horse's activities following sedation. Horses should not be ridden, worked, or placed in situations requiring full coordination until sedative effects have completely resolved.

If a scheduled dose of acepromazine is missed for ongoing behavioral management, it can generally be given when remembered without modification. Doses should never be doubled to compensate for missed administrations, as this increases the risk of excessive sedation and adverse effects. For pre-procedural sedation, timing is critical, and consultation with the veterinarian is appropriate if the planned dosing schedule cannot be followed.

Completion of acepromazine administration for specific procedures is determined by the clinical situation rather than a predetermined course. Once the intended procedure or activity is completed, no additional doses are typically required. For behavioral management protocols, the veterinarian determines the appropriate duration of treatment and any tapering requirements based on the individual case.

Acepromazine is generally well-tolerated in appropriately selected patients, but several important side effects occur with sufficient frequency to warrant awareness by horse owners and handlers. The drug's pharmacological mechanisms produce predictable effects beyond sedation, and understanding these helps differentiate expected responses from concerning adverse reactions. Close observation during and after acepromazine administration allows early recognition of problems requiring veterinary attention.

Hypotension is the most significant common side effect of acepromazine, resulting from alpha-adrenergic blockade and peripheral vasodilation. This effect is typically well-tolerated in healthy horses at appropriate doses but can cause significant clinical problems in compromised patients or with excessive dosing. Signs of hypotension include pale mucous membranes, prolonged capillary refill time, increased heart rate, weakness, and in severe cases, collapse. Intravenous administration produces more rapid and pronounced hypotensive effects than intramuscular injection, and slow IV administration may reduce this risk.

Penile prolapse represents a well-documented and potentially serious complication of acepromazine in stallions and geldings. The drug causes relaxation of the retractor penis muscles, allowing the penis to extend from the prepuce. While brief prolapse is usually benign, prolonged prolapse can result in penile paralysis, edema, trauma, and potentially permanent damage requiring penile amputation. The risk appears highest in draft breeds and following high doses or repeated administration. This side effect has led many veterinarians to avoid acepromazine entirely in breeding stallions and to use it cautiously in valuable performance geldings.

Central nervous system effects beyond intended sedation may include ataxia, swaying, and impaired coordination that can create safety risks for both horses and handlers. Sedated horses may stumble or fall, particularly on uneven ground or during procedures requiring positional changes. Rarely, paradoxical excitation occurs, with the horse becoming more agitated rather than sedated. This reaction may be more likely in horses that were highly excited before drug administration, as acepromazine's effects can be overcome by high catecholamine levels.

Other side effects include decreased body temperature due to vasodilation and reduced thermoregulatory capacity, which can be problematic in cold weather or with prolonged sedation. Sweating may occur in some horses. Gastrointestinal effects are generally minimal but may include mild decreases in gut motility. Acepromazine has no analgesic properties, and sedated horses may still react suddenly to painful stimuli, creating potential safety hazards for handlers who mistake sedation for pain control.

Acepromazine is contraindicated in horses with known hypersensitivity to phenothiazine compounds. Prior allergic reactions to acepromazine or related drugs indicate that the medication should not be used, and alternative sedatives should be selected. The veterinarian should be informed of any previous adverse reactions to sedatives before acepromazine administration.

Horses in shock, with significant blood loss, severe dehydration, or cardiovascular compromise should not receive acepromazine due to the risk of life-threatening hypotension. The alpha-adrenergic blockade caused by acepromazine can worsen hypotension in patients with already compromised circulation, potentially causing cardiovascular collapse. Alternative sedatives that do not produce significant vasodilation are preferred in hemodynamically unstable patients. Horses with heart disease or arrhythmias should be evaluated carefully before acepromazine use.

Acepromazine should be avoided or used with extreme caution in stallions and valuable geldings due to the risk of penile prolapse and potential permanent penile paralysis. Many veterinarians consider stallions to be relatively contraindicated for acepromazine use, preferring alpha-2 agonists for sedation when available. If acepromazine must be used in male horses, lower doses and careful monitoring are essential, and the veterinarian should be contacted immediately if penile prolapse is observed.

The use of acepromazine is generally avoided in horses that are already highly excited, frightened, or stressed, as the drug may be ineffective in these situations. High circulating catecholamine levels can override acepromazine's sedative effects, and the drug may produce unpredictable responses in highly aroused animals. Alpha-2 agonists typically provide more reliable sedation in excited horses and are preferred when calm handling cannot be achieved before sedation.

Pregnant mares may receive acepromazine when medically necessary, though caution is warranted particularly in late pregnancy. The drug crosses the placenta and may affect the fetus, and hypotensive effects could theoretically compromise placental perfusion. The veterinarian weighs the benefits of sedation against potential risks in each case. Competition horses are subject to drug testing, and acepromazine's long detection time makes it unsuitable for horses that will compete within the regulated withdrawal period.

Acepromazine interacts with numerous medications, and veterinarians should be informed of all current drugs before administration. The most significant interactions involve additive central nervous system depression with other sedatives and potential enhancement of hypotensive effects with various cardiovascular medications. Understanding these interactions supports safe use in horses receiving multiple medications.

Combination with other central nervous system depressants produces additive sedative effects that may result in excessive sedation, respiratory depression, or cardiovascular compromise. Alpha-2 agonists such as detomidine and xylazine are frequently combined intentionally with acepromazine to provide balanced sedation, but doses of both drugs are typically reduced when used together. Opioid analgesics similarly have additive effects with acepromazine and require dose adjustment. General anesthetic agents will have enhanced effects in horses that have received acepromazine premedication.

Antihypertensive medications and other drugs causing vasodilation may have enhanced hypotensive effects when combined with acepromazine. This is particularly relevant in older horses receiving cardiac medications or horses with conditions requiring blood pressure management. The veterinarian evaluates cardiovascular status and current medications before acepromazine administration and may select alternative sedatives in horses at risk for hypotension.

Epinephrine and other catecholamines may have altered effects in horses that have received acepromazine. The alpha-adrenergic blocking properties of acepromazine can result in paradoxical responses to epinephrine, with enhanced beta-adrenergic effects producing vasodilation and hypotension rather than the expected vasoconstriction. This interaction has implications for emergency treatment of anaphylaxis or cardiac arrest in acepromazine-sedated horses.

Organophosphate antiparasitic compounds may have enhanced toxicity in horses that have received acepromazine, as phenothiazines can inhibit cholinesterase activity. While this interaction is rarely clinically significant with modern deworming practices, it should be considered in horses with recent organophosphate exposure. Procaine and other ester-type local anesthetics are metabolized by the same esterases and could theoretically have altered effects, though this is not typically a practical concern.

For competition horses, the primary interaction concern involves acepromazine's prohibited status and long detection time. Drug testing protocols can detect acepromazine metabolites for extended periods, and the drug is classified as a prohibited substance under FEI, USEF, and racing commission rules. Withdrawal times must account for this prolonged detection window.

Careful patient monitoring during acepromazine sedation allows early detection of adverse effects and ensures safe outcomes. Baseline cardiovascular assessment including heart rate, rhythm, and mucous membrane color provides reference points for detecting hypotension or other complications. Continuous observation during the sedation period allows prompt response to problems including excessive sedation, hypotension, or ataxia severe enough to risk injury.

Special precautions apply to specific patient populations. Foals and young horses may be more sensitive to acepromazine's effects and typically require lower doses per kilogram than adult horses. Elderly horses may have reduced hepatic metabolism and increased sensitivity, also warranting conservative dosing. Debilitated horses, horses recovering from illness or surgery, and horses with anemia should be evaluated carefully, as these patients are at higher risk for hypotension-related complications.

Acepromazine is classified as a prohibited substance by equine competition governing bodies including the FEI, USEF, and state racing commissions. The drug has a notoriously long detection time due to persistent metabolites, with positive tests possible for an extended period after administration. Detection times vary based on dose, route, and individual metabolism, but conservative estimates suggest withdrawal periods of at least two to four weeks for competition horses. Current rules should always be verified, as regulations and detection thresholds change over time.

Safe handling of acepromazine-sedated horses requires recognition that sedation does not equal unconsciousness or complete lack of responsiveness. Horses may still respond suddenly to stimuli, and handlers should remain alert even with sedated patients. Adequate support should be available if the horse becomes unstable, and procedures should be performed in safe environments where the horse cannot injure itself or handlers if it falls or stumbles.

Environmental considerations include temperature management, as acepromazine impairs thermoregulation through vasodilation. Horses sedated with acepromazine in cold weather may require blanketing, while those sedated in hot weather may need cooling support. Transportation of acepromazine-sedated horses should account for weather conditions in the trailer, and horses should be monitored for signs of thermal stress.

Acepromazine solutions and tablets should be stored according to manufacturer specifications to maintain potency and stability. Injectable solutions typically require storage at controlled room temperature between fifteen and thirty degrees Celsius, protected from light and freezing. Exposure to excessive heat, direct sunlight, or freezing can degrade the medication and reduce its effectiveness. Storage in the typical barn environment may be acceptable if temperature extremes are avoided, but climate-controlled storage is preferable.

Proper handling of acepromazine during preparation and administration maintains sterility and ensures accurate dosing. Injectable solutions should be inspected visually before each use to confirm clarity and absence of particulate matter or discoloration. Syringes and needles should be sterile, and aseptic technique should be used when withdrawing medication from multi-dose vials. Oral formulations should be kept in original containers to protect from moisture and light.

Disposal of unused acepromazine and associated supplies follows standard pharmaceutical waste protocols. Expired medications should be disposed of properly rather than administered, and unused portions from opened vials should be handled according to local regulations. Needles and syringes require disposal in approved sharps containers to prevent accidental needle sticks. Horse owners should consult with their veterinarian or local waste management authority regarding proper disposal procedures.

Expired acepromazine should never be administered to horses. The expiration date represents the manufacturer's guarantee of potency and safety, and degraded medication may have reduced efficacy or altered properties that could affect patient response. Any acepromazine solution showing discoloration, cloudiness, or precipitate formation should be discarded even if within the labeled expiration period. Regular inventory checks ensure that expired products are identified and removed from use.

Draft horses and other large breeds present specific considerations for acepromazine use. While the drug is effective across all horse sizes, draft breeds appear to have increased susceptibility to penile prolapse following acepromazine administration. This documented breed predisposition has led many veterinarians to avoid or minimize acepromazine use in draft stallions and geldings when alternative sedatives are available. When acepromazine must be used in draft horses, conservative dosing and vigilant monitoring for penile complications are essential.

Light horse breeds and Warmbloods generally respond predictably to acepromazine at standard doses. Individual variation exists, with some horses being highly sensitive and others relatively resistant to the drug's effects. Horse owners who have previous experience with acepromazine in their individual horse can provide valuable information about expected response, helping veterinarians adjust doses appropriately. Performance horses face particular concerns regarding the drug's long detection time and prohibited status in competition.

Ponies and miniature horses require careful weight-based dosing, as overestimation of body weight can result in relative overdosing with enhanced risk of adverse effects. The maximum recommended total dose limitations apply regardless of weight, providing an additional safety check for smaller equines. Some veterinarians report that ponies may be somewhat more sensitive to acepromazine's effects, though this is not universally documented.

Arabians and other hot-blooded breeds are sometimes reported to show more pronounced or prolonged sedation with acepromazine, though individual variation is significant. Conversely, excitable individuals of any breed may show reduced response, particularly if highly aroused at the time of administration. Breed-related behavioral tendencies influence drug selection and dosing strategies more than specific pharmacokinetic differences.

No specific genetic conditions in horses are known to significantly alter acepromazine metabolism or increase adverse reaction risk beyond the general considerations discussed. The increased penile prolapse risk in draft breeds appears related to anatomical factors rather than pharmacogenetic differences. Horses of all breeds with cardiovascular disease, hemodynamic compromise, or other conditions affecting drug handling require individualized assessment regardless of breed background.

Alpha-2 adrenergic agonists including detomidine, xylazine, and romifidine represent the primary alternatives to acepromazine for equine sedation. These drugs provide both sedation and analgesia, making them preferred for painful procedures. Alpha-2 agonists typically produce more reliable sedation in excited horses and have more predictable dose-response relationships than acepromazine. However, they produce more significant cardiovascular effects including bradycardia and atrioventricular block, and their shorter duration of action may be disadvantageous for some applications. Alpha-2 agonists and acepromazine are frequently combined in balanced sedation protocols that leverage the benefits of both drug classes.

Benzodiazepines including diazepam and midazolam are occasionally used for sedation in horses, though they are less effective as standalone sedatives compared to acepromazine or alpha-2 agonists. Benzodiazepines provide muscle relaxation and anticonvulsant effects and are valuable components of anesthetic protocols. They may be combined with other sedatives for enhanced effect and are particularly useful in foals and debilitated patients where cardiovascular stability is paramount.

Opioid analgesics such as butorphanol are frequently combined with acepromazine or alpha-2 agonists to provide analgesia for painful procedures. Opioids alone do not provide adequate sedation in horses and may cause excitation when used without concurrent sedatives. The combination of acepromazine and butorphanol provides sedation with some degree of analgesia, though alpha-2 agonist combinations generally offer superior pain control.

Non-sedative calming supplements and medications may be considered for chronic anxiety management or situations where prescription sedatives are not appropriate. These products have variable efficacy and are not substitutes for veterinary sedatives when significant calming is required. Horse owners should consult with their veterinarian regarding appropriate options for their horse's specific needs, and substitution of prescription sedatives with over-the-counter products should only be done with professional guidance.